FDA is disputing a GAO account of ongoing drug shortages, and argued during a congressional hearing they are plateauing, rather than increasing.
While the Government Accountability Office counted each specific product that had undergone a shortage, FDA told the House Energy and Commerce Health Subcommittee that it deemed a shortage to be...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?